<DOC>
	<DOCNO>NCT01037309</DOCNO>
	<brief_summary>The purpose study see whether PRO044 safe effective use medication DMD patient mutation around location 44 DNA dystrophin protein .</brief_summary>
	<brief_title>Phase I/II Study PRO044 Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>To assess effect PRO044 different dose level subject Duchenne muscular dystrophy To assess safety tolerability PRO044 different dose level subject Duchenne muscular dystrophy To determine pharmacokinetics PRO044 different dose level subcutaneous intravenous administration subject Duchenne muscular dystrophy .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>1 . Boys age 5 16 year inclusive . 2 . Duchenne muscular dystrophy result mutation correctable treatment PRO044 . 3 . Life expectancy least 6 month . 4 . No previous treatment investigational medicinal treatment within 6 month prior start ( pre ) screening study . 5 . No previous treatment idebenone within 6 month prior start ( pre ) screening study . 6 . Willing able adhere study visit schedule protocol requirement . 7 . Written inform consent sign ( parent ( ) /legal guardian and/or patient , accord local regulation ) . 8 . Glucocorticosteroids use stable least 2 month prior first drug administration . 1 . Aberrant RNA splice and/or aberrant response PRO044 , detect vitro PRO044 assay prescreening . 2 . Known presence dystrophin â‰¥ 5 % fiber prestudy diagnostic muscle biopsy . 3 . Severe muscle abnormality define increased signal intensity &gt; 50 % tibialis anterior muscle MRI . 4 . FEV1 and/or FVC &lt; 60 % predict . 5 . Current history liver renal disease . 6 . Acute illness within 4 week prior treatment ( Day 1 ) may interfere measurement . 7 . Severe mental retardation opinion investigator prohibit participation study . 8 . Severe cardiac myopathy opinion investigator prohibit participation study . 9 . Need mechanical ventilation . 10 . Creatinine concentration 1.5 time upper limit normal ( age correct ) . 11 . Serum ASAT and/or ALAT concentration ( ) suggest hepatic impairment . 12 . Use anticoagulant , antithrombotics antiplatelet agent . 13 . Use idebenone . 14 . Use investigational product within 6 month prior start ( pre ) screening study . 15 . Subject donate blood le 90 day start ( pre ) screening study . 16 . Current history drug and/or alcohol abuse . 17 . Participation another trial investigational product .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>